Clinical Trial Update: A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) [Phase 2]

View source ↗

Summary

Phase 2 long-term study of bivamelagon in hypothalamic obesity is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypothalamic Obesity

Drugs mentioned

• Bivamelagon

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Hypothalamic Obesity | Phase 2 | Status: ENROLLING_BY_INVITATION